Literature DB >> 9688367

Relationship of ovarian stromal volume to serum androgen concentrations in patients with polycystic ovary syndrome.

A A Kyei-Mensah1, S LinTan, J Zaidi, H S Jacobs.   

Abstract

The aim of this study was to investigate of the relationship of ovarian stromal volume, measured using three-dimensional ultrasound, to serum androgen concentrations in patients with polycystic ovaries. Serum gonadotrophin, oestradiol and androgen concentrations and ovarian volume measurements were obtained in the early follicular phase from 100 women undergoing assisted conception treatment cycles. Group 1 contained 50 women with regular menstrual cycles and normal ovarian morphology, group 2 contained 24 women with regular menstrual cycles and polycystic ovaries seen on ultrasound scan and group 3 contained 26 women with polycystic ovary syndrome. Statistical analysis included analysis of variance, Scheffé's procedure and Pearson's correlation. Total ovarian volume (15.7-16.1 versus 11 ml, P < 0.05), stromal volume (14.5 versus 9.4 ml, P < 0.05) and thecal steroid concentrations were significantly greater in groups 2 and 3. Stromal volume was positively correlated with serum androstenedione concentrations (r = 0.45, P = 0.0019 in group 3) but was not correlated with any other endocrine parameter. It was concluded that polycystic ovaries are characterized by increased ovarian stroma with associated overproduction of theca-derived steroids, particularly androstenedione.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9688367     DOI: 10.1093/humrep/13.6.1437

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

1.  Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome.

Authors:  Sarantis Livadas; Christos Pappas; Athanasios Karachalios; Evangelos Marinakis; Nikoleta Tolia; Maria Drakou; Philippos Kaldrymides; Dimitrios Panidis; Evanthia Diamanti-Kandarakis
Journal:  Endocrine       Date:  2014-04-22       Impact factor: 3.633

2.  Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features.

Authors:  Melissa Pawelczak; Lisa Kenigsberg; Sarah Milla; Ying-Hua Liu; Bina Shah
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

3.  Predictive value of ovarian stroma measurement for cardiovascular risk in polycyctic ovary syndrome: a case control study.

Authors:  Giuseppe Loverro; Giovanni De Pergola; Edoardo Di Naro; Massimo Tartagni; Cristina Lavopa; Anna Maria Caringella
Journal:  J Ovarian Res       Date:  2010-11-09       Impact factor: 4.234

4.  Ovarian volumes among women with endometrial carcinoma: associations with risk factors and serum hormones.

Authors:  Mark E Sherman; M Patricia Madigan; James V Lacey; Montserrat Garcia-Closas; Nancy Potischman; Joseph D Carreon; Patricia Hartge; Louise A Brinton
Journal:  Gynecol Oncol       Date:  2007-08-27       Impact factor: 5.482

5.  Racial differences in self-reported infertility and risk factors for infertility in a cohort of black and white women: the CARDIA Women's Study.

Authors:  Melissa F Wellons; Cora E Lewis; Stephen M Schwartz; Erica P Gunderson; Pamela J Schreiner; Barbara Sternfeld; Josh Richman; Cynthia K Sites; David S Siscovick
Journal:  Fertil Steril       Date:  2008-03-05       Impact factor: 7.329

6.  Clarifying the role of three-dimensional transvaginal sonography in reproductive medicine: an evidenced-based appraisal.

Authors:  Nick Raine-Fenning; Arthur C Fleischer
Journal:  J Exp Clin Assist Reprod       Date:  2005-08-11

7.  Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome.

Authors:  Sungwook Chun
Journal:  Clin Exp Reprod Med       Date:  2014-06-30

Review 8.  Involvement of androgens in ovarian health and disease.

Authors:  M Lebbe; T K Woodruff
Journal:  Mol Hum Reprod       Date:  2013-09-10       Impact factor: 4.025

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.